Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation.

Simple item page
dc.contributor.authorSalvatierra, Juan
dc.contributor.authorAomar-Millán, Ismael Francisco
dc.contributor.authorHernández-Quero, José
dc.date.accessioned2025-01-07T13:58:40Z
dc.date.available2025-01-07T13:58:40Z
dc.date.issued2021-03-08
dc.identifier.doi10.1016/S2665-9913(21)00064-3
dc.identifier.essn2665-9913
dc.identifier.pmcPMC7990485
dc.identifier.pmid33782671
dc.identifier.pubmedURLhttps://pmc.ncbi.nlm.nih.gov/articles/PMC7990485/pdf
dc.identifier.unpaywallURLhttp://www.thelancet.com/article/S2665991321000643/pdf
dc.identifier.urihttps://hdl.handle.net/10668/26010
dc.issue.number4
dc.journal.titleThe Lancet. Rheumatology
dc.journal.titleabbreviationLancet Rheumatol
dc.language.isoen
dc.organizationSAS - Hospital Universitario San Cecilio
dc.organizationSAS - Hospital Universitario San Cecilio
dc.page.numbere248
dc.pubmedtypeJournal Article
dc.rights.accessRightsopen access
dc.titleInterleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number3

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
PMC7990485.pdf
Size:
119.3 KB
Format:
Adobe Portable Document Format
Download

Collections

SAS - Hospital Universitario San Cecilio

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía